Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

SciClone and Menarini Submit NDA for Vaborem in China

Fineline Cube Jan 17, 2025

China-based SciClone Pharmaceuticals Inc and its Italy-based strategic partner Menarini have announced the submission of...

Company Deals

Servier and Google Cloud Extend Partnership to Advance AI in Drug Development

Fineline Cube Jan 17, 2025

France-based Servier Group and US technology firm Google Cloud have announced an expansion to their...

Company Deals

Cathay Biotech Plans $901M Private Placement to Boost Bio-Based Materials

Fineline Cube Jan 17, 2025

Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD...

Company Deals

Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037

Fineline Cube Jan 17, 2025

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm...

Company Medical Device

Boston Scientific’s FARAPULSE and WATCHMAN FLX Studies Show Positive Results

Fineline Cube Jan 17, 2025

US major Boston Scientific Corporation (NYSE: BSX) has announced the presentation of positive results from...

Company Drug

Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials

Fineline Cube Jan 17, 2025

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...

Company Drug

Zhejiang Huahai’s HB0056 Approved for US Phase I Asthma Trial

Fineline Cube Jan 17, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval from...

Company Drug

Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials

Fineline Cube Jan 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...

Company Drug

CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials

Fineline Cube Jan 17, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...

Company Drug

Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment

Fineline Cube Jan 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...

Company

ConjuStar Completes $15 Million Pre-A+ Financing Round

Fineline Cube Jan 17, 2025

ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...

Company Deals

Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey

Fineline Cube Jan 16, 2025

On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...

Company Deals

GE Healthcare and Sutter Health Form $1B Care Alliance

Fineline Cube Jan 16, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has formed...

Company Drug

HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China

Fineline Cube Jan 16, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...

Company Drug

Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer

Fineline Cube Jan 16, 2025

China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...

Company Drug

Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial

Fineline Cube Jan 16, 2025

China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval...

Company Drug

Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment

Fineline Cube Jan 16, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

Hengrui’s SHR-9839 Receives NMPA Clearance for Advanced Tumors

Fineline Cube Jan 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical clearance from the...

Legal / IP

Chipscreen’s Epidaza Patent Faces Invalidation Request Review

Fineline Cube Jan 16, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...

Company Deals

Biogen Proposes to Acquire Sage Therapeutics for $469M

Fineline Cube Jan 15, 2025

US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal...

Posts pagination

1 … 166 167 168 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.